===
Curatis Holding AG / Key word(s): Annual Results/Personnel
Curatis Holding AG publishes Annual Report of the (then still named) Kinarus Group for FY2023 and announces appointment
of Chief Financial Officer
24-May-2024 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.
Ad hoc announcement pursuant to Art. 53 LR
. Full Annual Report of Kinarus Therapeutics Holding AG for the financial year 2023 published today

. Publication of audited consolidated & statutory FY2023 financial statements of Kinarus Therapeutics
Holding AG already occurred on 17 April 2024
. Patrick Ramsauer appointed as Chief Financial Officer of Curatis Holding AG with immediate effect
Liestal, Switzerland, 24 May 2024: Curatis Holding AG (CURN.SW), previously Kinarus Therapeutics Holding AG (together
with its subsidiaries "Curatis Group", or the "Company"), a SIX Swiss Exchange listed specialty pharmaceutical and
therapeutic drug development company focused on orphan and ultra-orphan indications today published its annual report
for FY2023. The audited consolidated FY2023 financial statements and the audited statutory FY2023 financial statements
of the Company, together the audited "FY2023 Financial Statements", had already been published on 17 April 2024. Both,
Kinarus Therapeutics Holding AG and its 100% subsidiary, Kinarus AG in Liquidation had filed for bankruptcy in October
2023, but on 5 February 2024, bankruptcy of Kinarus Therapeutics Holding AG was revoked by the competent courts of
Basel-Stadt to pave the way for the business combination of Kinarus Therapeutics Holding AG and Curatis AG, a
Basel-Landschaft incorporated specialty medicine distribution and drug development company (the "Business Combination
"), which was completed on 26 April 2024. Kinarus AG in Liquidation remains in liquidation. The 2023 Annual Report of
Kinarus Group therefore does not provide a comprehensive and transparent picture on the effective situation of the
Company today after the completion of the Business Combination of Kinarus Therapeutics Holding AG with Curatis AG.
Furthermore, the Company announced today that it has appointed Patrick Ramsauer as Chief Financial Officer in a part
time role with immediate effect.
Patrick Ramsauer has a strong finance background and has extensive experience from various financial roles, in
Corporate Finance at UBS AG, as founder of RBR Capital, an asset management company focused on Swiss and European
Equities, in Business Development for Palantir, a US AI and Data Technology company as well as in his role as CFO of an
emerging data integration technology company since 2021. Patrick Ramsauer holds a Masters degree in Finance from the
University of Zurich, Switzerland. Since spring 2023 he is a Partner at Yuma Capital, a boutique corporate finance &
capital advisory firm, and has in this role amongst others supported Curatis in the recent business combination with
Kinarus. Curatis has found en excellent candidate to fill this vacant position, and is convinced that Patrick
Ramsauer's knowledge and experience in finance and data technology will greatly complement Curatis' Executive
Management Team.
About the Curatis Group:
Curatis Holding AG is a publicly listed specialty pharmaceutical company with a distribution and drug development
business. The focus of the Curatis Group's business activities is on high unmet medical need orphan and ultra-orphan
indications, pursued via its wholly owned operating subsidiary Curatis AG. The Curatis Group was formed by the Business
Combination of Kinarus Therapeutics Holding AG and Curatis AG in April 2024.
Investor Relations Contact:
YUMA Capital
Thomas Bieri
Managing Partner
Tel: +41 44 575 2201
thomas.bieri@yuma-capital.com
Disclaimer
The information contained in this media release and in any link to our website indicated herein is not for use within
any country or jurisdiction or by any persons where such use would constitute a violation of law. If this applies to
you, you are not authorized to access or use any such information.
This media release contains "forward-looking statements" that are based on our current expectations, assumptions,
estimates and projections about us and our industry. Forward-looking statements include, without limitation, any
statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain
the words "may", "will", "should", "continue", "believe", "anticipate", "expect", "estimate", "intend", "project",
"plan", "will likely continue", "will likely result", or words or phrases with similar meaning. Undue reliance should
not be placed on such statements because, by their nature, forward-looking statements involve risks and uncertainties,
including, without limitation, economic, competitive, governmental and technological factors outside of the control of
Curatis Group, that may cause Curatis' business, strategy or actual results to differ materially from the
forward-looking statements (or from past results). For any factors that could cause actual results to differ materially
from the forward-looking statements contained in this media release, please see our listing prospectus in connection
with the Business Combination. Curatis Group undertakes no obligation to publicly update or revise any of these
forward-looking statements, whether to reflect new information, future events or circumstances or otherwise. It should
further be noted that past performance is not a guide to future performance. Persons requiring advice should consult an
independent adviser.
The information contained in this media release is not an offer to sell or a solicitation of offers to purchase or
subscribe for securities. This media release is not a prospectus within the meaning of the Swiss Financial Services Act
nor a prospectus under any other applicable laws.
Some financial information in this media release has been rounded and, as a result, the figures shown as totals in this

media release may vary slightly from the exact arithmetic aggregation of the figures that precede them.  
End of Inside Information  
Language:     English 
Company:      Curatis Holding AG 

Weierweg 7
4410 Liestal
Switzerland

ISIN:         CH1330780979 
Listed:       SIX Swiss Exchange 
EQS News ID:  1910239 

End of Announcement EQS News Service
===
1910239 24-May-2024 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1910239&application_name=news

END) Dow Jones Newswires

May 24, 2024 01:00 ET (05:00 GMT)